84 results about "Metastatic cell" patented technology

The present invention provides a method of identifying origin of a metastasis of unknown origin by obtaining a sample containing metastatic cells; measuring Biomarkers associated with at least two different carcinomas; combining the data from the Biomarkers into an algorithm where the algorithm normalizes the Biomarkers against a reference; and imposes a cut-off which optimizes sensitivity and specificity of each Biomarker, weights the prevalence of the carcinomas and selects a tissue of origin determining origin based on highest probability determined by the algorithm or determining that the carcinoma is not derived from a particular set of carcinomas; and optionally measuring Biomarkers specific for one or more additional different carcinoma, and repeating the steps for additional Biomarkers.

The present invention provides methods for the assessment of the metastatic potential of cells by measuring the effect of the cells on the impedance of an electrode. Accordingly, the present invention similarly provides methods for establishing indicators of metastatic potential based on a cell's effect on impedance. Such methods may be employed in vitro or in vivo. In some embodiments, the electrode is coated with endothelial or epithelial cells.

A diagnostic device includes a microscope configured to obtain image data on a plurality of cells and a computing device. The computing device is configured to receive the image data, identify at least a portion of each of the plurality of cells based on the received image data, determine at least one of a value of a morphological parameter for each identified at least a portion of the plurality of cells or a relative organization among the identified at least a portion of the plurality of cells, and calculate statistics for the plurality of cells based on the at least one of the determined values of the morphological parameter or the determined relative organization, the statistics including information suitable for distinguishing metastatic cells from non-metastatic cells. The diagnostic device further includes an output device configured to output the statistics for diagnosis.

The present invention relates to a distinct B cell subset, B10 cells, that regulate T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of B10 cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of B10 cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of B10 cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, ameliorate infectious diseases and / or to treat tumors / cancer. Diagnostic applications are also encompassed.

The present invention features methods and compositions for identifying markers of minimum residual disease (MRD), as well as markers of metastatic cells. The present invention further provides methods for detecting MRD and metastatic cell in a subject.

The present invention relates to a method and system for analyzing mechanical signatures of a plurality of cells for metastatic detection. Specifically, a data set characterized by at least one metric (such as Brillouin frequency shift and / or Brillouin linewidth) representing a cell mechanical signature is acquired for the plurality of cells by using a label-free Brillouin spectroscopy. A merit function is calculated based on one or more statistical characteristics of the data set, such as sensitivity and specificity. Then, the plurality of cells can be classified to detect metastatic cells based on mechanical signatures provided by the data set and an optimal metric value delivering maximum to the merit function.

The invention discloses an in vitro model simulating human tumor metastasis. Cells in the model have a tumor high metastasis character. The model is constructed by building of a micro spherical hydrogel support frame by tumor high metastasis cells, building of a tumor cell in vitro metastasis model and identifying of the constructed tumor cell in vitro metastasis model. The model can grow in a three-dimensional culturing cell in a clustering mode, and tumor cell biological behaviors in metastasis can be detected. The model has important value in studying of a clinical tumor metastasis mechanism and controlling of screening of metastasis medicine and can be taken as a technical platform for manufacturing anti-tumor metastasis gene vaccines and building screening of anti-tumor metastasis medicine.

The invention belongs to the field of micro-organism animal cell line and relates to a human hepatoma cell line which can emit high-intensity red or green fluorescence and has high transferring ability of lung and lymph node metastasis, and a method for establishing the same. The method comprises the following steps: using the human hepatoma cell line HCCLM3 and HCCLM6 which have high transferring ability of the lung and lymph node metastasis as mother cells, performing cotransfection on plasmid DNA of 239 cells through slow virus packaging plasmids to obtain false slow virus particles by expressing red or green fluorescent protein genes through eucaryon, and infecting liver cancer cell strains of the mother cells to obtain the chromosome integrated hepatoma cell line which has high transferring ability of the lung and lymph node metastasis and can stably expressing the red or the green fluorescence. The human hepatoma cell line which has high transferring ability of the lung and lymph node metastasis in vitro can be applied to the tracer studies on tumor cells, the molecular mechanism studies on the recurrence and transferring of liver cancer, as well as the pre-clinical drug efficacy studies on new anti-tumor drugs, thus the human hepatoma cell line has wide application prospect.

The present invention provides methods for the assessment of the metastatic potential of cells by measuring the effect of the cells on the impedance of an electrode. Accordingly, the present invention similarly provides methods for testing the efficacy of anti-cancer therapies and for establishing indicators of metastatic potential based on a cell's effect on impedance. Such methods may be employed in vitro or in vivo. In some embodiments, the electrode is coated with endothelial or epithelial cells. A first aspect of the invention provides a method of assessing a metastatic potential of a cell comprising the steps of providing an electrode coated with a plurality of substrate cells, obtaining a first measurement of at least one electrical property of the coated electrode, contacting the electrode with at least one test cell, obtaining a second measurement of at least one electrical property of the coated electrode, and comparing the first and second measurements.

The invention discloses BrBP1 polypeptide in specific binding with breast cancer brain metastases cells, and further relates to a preparation method of the polypeptide. The method includes: by utilization of phage display technology, carrying out a plurality of rounds of whole-cell depletion screening, and screening out phage clones bound with a breast cancer brain metastases cell line; randomly picking out a plurality of the phage clones, and selecting strongly positive phage clones with a cell enzyme-linked immuno sorbent assay (ELISA) method; and after increasing the strongly positive phage clones, carrying out sequencing, and synthesizing the tested BrBP1 polypeptide in a manual mode. The polypeptide can be applied to preparation of medicine used for curing breast cancer brain metastases and kits used for early-stage diagnosis of the breast cancer brain metastases. The polypeptide can be synthesized with a manual method, is small in molecular weight, high in activity, strong in penetrating power, high in affinity and specificity and low in toxicity, has good tumor-targeting performance inside and outside a body, can also be internalized to enter cells, and is suitable for being used as vectors for targeted therapy.

Disclosed herein are compositions and methods for the treatment of liver metastases in a subject. The methods include hepatic arterial infusion (HAI) of chimeric antigen receptor modified T cells (CAR-T) which are highly specific for tumor antigens such as carcinoembryonic antigen (CEA). The HAI method is optimized to maximize exposure of the modified cells to the metastatic cells while minimizing exposure to healthy cells. The methods include co-administration of a second therapeutic agent, such as IL-2.

The invention discloses a highly metastatic model of human melanoma, a highly metastatic cell subline of the human melanoma, creation methods for the highly metastatic model and the highly metastatic cell subline, and the dynamic detection of metastasis. The subcutaneously-transplanted mouse highly metastatic model and the corresponding cell subline are established in an in-vivo screening way in a mouse with severe combined immune deficiency (SCID) by using mouse lung metastasis, namely human malignant melanoma cell strain A375 pulmonary metastasis, wherein the highly metastatic cell subline of the human melanoma is A375sci, and has a human tumor cell karyotype; and 60 to 75 hypo-triploid-dominated chromosomes are acrocentric and have a heteroploid karyotype. The cell subline has the two routes of metastasis of blood trails and lymph. The in-vivo screening of the highly-metastatic model is performed by using animals with severe immune deficiency, and is expressed and applied in nude mice. A method for detecting Alu genes by using a polymerase chain reaction (PCR) method is simple, highly sensitive and highly specific, and can be used for detecting organ metastasis, particularly micrometastasis, in a human tumor animal-xenotransplantation model.

Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and / or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell.

Conventional cancer immunotherapy falls short at efficiently expanding T cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with MHC class I and / or class II molecules presenting tumor-specific antigens and co-stimulatory molecules and their use to expand antigen-specific anti-tumorigenic T cellsto levels not achieved in current immunotherapeutic techniques. These antigen-specific anti-tumorigenic T cells include cytotoxic T cells, effector T cells, memory T cells, and helper T cells that are necessary to initiate and maintain a substantial immune response against metastatic or non- metastatic cancerous, pre-cancerous, or neoplastic cells in vivo.; The present invention describes a systemic approach to targeting cancerous or pre-cancerous cells that are circulating cells, as in lymphomas, migratory metastatic cells, and solid tumors.

The human HLJ1 tumor suppressor gene is herein defined as regulated by promoter, enhancer, and silencer regions. HLJ1 promoter activity and gene expression are inversely correlated with metastatic ability. HLJ1 is highly expressed, and inducible, in cells with low metastatic ability and expressed to a lesser extent in highly metastatic cells. HLJ1 gene expression suppressed the growth of human lung adenocarcinoma cells in vitro, and inhibited tumor growth in vivo. It also impeded the motility of human adenocarcinoma cells and reduced the anchorage-independent growth capacity and invasiveness of metastatic lung adenocarcinoma cells. The degree to which human lung adenocarcinoma patients express HLJ1 predicts their survival prognosis and their probability of relapse.

The invention discloses a biology activity determination method of a monoclonal antibody of a recombined anti-human epidermal growth factor receptor. The method comprises the following steps: incubating human lung cancer-lymph node metastasis cells H292 and anti-EGFR monoclonal antibody with different concentrations; adding a cell counting dye reagent CCK-8; determining the light absorption value of stained vital cells through a microplate reader; processing experiment data through a computer program; calculating the biology activity of an anti-EGFR sample relative to an anti-EGFR standard. According to the invention, a cell strain with the detected cells H292 is applicable to antibodies with different affinities, the cell culture time is short, and the needed cell quantity is less; staining fluid of an MTT colorimetric method is improved, CCK-8 staining fluid is used, the product solubility is good, further solution treatment is not needed, the detection result can be detected at different time after the staining fluid is added, the developing result is stable, and the quality is controllable. The biology activity determined by the method is related to clinical effects, thus meeting the relevant technical requirement of FDA.

Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic; hyperproliferative, and / or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell.

Arylquinoline derivatives and their use for treating cancer or cancer metastasis is disclosed. The compounds of the subject technology promote cells to secrete a pro-apoptotic tumor suppressor, i.e., prostate apoptosis response-4 (Par-4), which in turn promote apoptosis in cancer cells or metastatic cells.

The disclosure is directed to compositions comprising an oncolytic virus, chimeric antigen receptor T cells (CAR T cells), a therapeutic or immunomodulating monoclonal antibody, a targeting thymidine kinase inhibitor (TKI), or an adoptively transferred cells incorporating engineered T cell receptors, and a live attenuated recombinant Listeria strain comprising a fusion protein of a Truncated LLO, a truncated ActA or a PEST-sequence peptide fused to a tumor-associated antigen. The disclosure is further directed to methods of treating, protecting against, and inducing an immune response against a tumor, comprising the step of administering the same, with or without an additional radiation therapy treatment.

The invention relates to a method for preparing breast cancer bone metastasis organs, which comprises the following steps: mixing breast cancer bone metastasis cells, feeder layer cells, a temperature-sensitive hydrogel and a first culture medium, and culturing to obtain breast cancer bone metastasis organs; wherein the feeder layer cells comprise bone marrow mesenchymal stem cells without a proliferation function. By means of the technical scheme, the bone marrow mesenchymal stem cells without the proliferation function are used as feeder layer cells for breast cancer bone metastasis organ culture, and the success rate of breast cancer bone metastasis organ culture through the method is high.

Metadherin, a protein that controls metastasis, and variants of metadherin are described. DNA sequences encoding the same and methods of production are described. Therapies involving the application of metadherin, binding agents that bind to metadherin, such as antibodies, and expression modulating agents, such as siRNA, are described. The use of metadherin or metadherin variants for delivering desired substances to particular lung tissue is described. A method of diagnosing metastatic cells based on the presence of metadherin is described.

The invention provides a fluorescence labeled human triple-negative breast cancer osseous metastasis cell line. The fluorescence labeled human triple-negative breast cancer osseous metastasis cell line is prepared with a method as follows: a human triple-negative breast cancer cell MDA-MB-231 is cultured; a lentivirus carrier containing RFP (red fluorescence protein) is amplified, and an RFP labelled MDA-MB-231 cell is prepared; the RFP-MDA-MB-231 cell is transplanted to the fourth pair breast fat pad position of a nude mouse and grows into tumor; shin bone of a hind limb is taken after 4-6 weeks, bone marrow is flushed with a buffer solution and digested with collagenase, a single cell from the bone marrow is obtained, in-vitro culture amplification is performed, and red fluorescence cells are sorted with a flow cytometry; through tumor formation screening in a body of the nude mouse, the red fluorescence labelled MDA-MB-231 human triple-negative breast cancer osseous metastasis cellline is obtained. The human triple-negative breast cancer osseous metastasis cell line has the characteristics of osseous metastasis, is labelled by fluorescent protein and realizes visualization andtraceability.

Compositions and methods for modulating tumor proliferation in an individual are provided. The methods employ nucleolin-binding agents, such as aptamers. The aptamers of the present invention can be used to modulate the proliferation of malignant, dysplastic, hyperproliferative, and / or metastatic cells through interference with molecular interactions and functions of nucleolin in the tumor cell.

Substances and methods are disclosed for reducing or preventing metastatic behaviour in VGSC expressing cancer by the effect of at least reducing the persistent part of the voltage gated sodium channel current without eliminating the transient part. Inhibition of metastatic cell behaviours such as detachability, lateral motility, transverse migration and invasiveness is demonstrated using the known drugs ranolazine and riluzole.